# Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma

> **NCT07524413** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 514 (estimated)

## Conditions studied

- Nasopharyngeal Cancinoma (NPC)
- Nasopharyngeal Cancer

## Interventions

- **DRUG:** Becotatug Vedotin
- **DRUG:** Pucotenlimab
- **DRUG:** Gemcitabine + cisplatin (GP)
- **RADIATION:** intensity-modulated radiotherapy
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT07524413
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2030-04
- **Final completion:** 2032-04
- **Target enrollment:** 514 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07524413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07524413, "Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07524413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*